Salta al contenuto principale
Ricerc@Sapienza
Toggle navigation
Home
Login
Home
Persone
maurizio.martelli@uniroma1.it
Maurizio Martelli
Professore Ordinario
Struttura:
DIPARTIMENTO DI MEDICINA TRASLAZIONALE E DI PRECISIONE
E-mail:
maurizio.martelli@uniroma1.it
Pagina istituzionale corsi di laurea
Curriculum Sapienza
Pubblicazioni
Titolo
Pubblicato in
Anno
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL
BREAST
2022
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors
JOURNAL OF CLINICAL MEDICINE
2022
CML Resistant to 2nd-Generation TKIs: Mechanisms, Next Steps, and New Directions
CURRENT HEMATOLOGIC MALIGNANCY REPORTS
2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors
CURRENT OPINION IN ONCOLOGY
2022
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study)
HEMATOLOGICAL ONCOLOGY
2022
Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges
INTERNATIONAL JOURNAL OF HEMATOLOGY
2022
Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement
HEMATOLOGICAL ONCOLOGY
2022
RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
BLOOD ADVANCES
2022
Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2022
Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement
HEMATOLOGICAL ONCOLOGY
2022
Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment
CANCERS
2022
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care
EXPERT REVIEW OF HEMATOLOGY
2022
Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients
SUPPORTIVE CARE IN CANCER
2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study
HEMATOLOGICAL ONCOLOGY
2022
Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study
BLOOD
2022
Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial
BRITISH JOURNAL OF HAEMATOLOGY
2022
Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall
BRITISH JOURNAL OF HAEMATOLOGY
2022
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
HAEMATOLOGICA
2022
Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
BLOOD
2022
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
THE LANCET. HAEMATOLOGY
2022
« prima
< precedente
1
2
3
4
5
6
7
8
seguente ›
ultima »
© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma